Similarly, in a study employing copy number variation analysis in tumors from 59 PCa patients, SCPC tumors revealed RB1 loss, TP53 mutations, amplification of aurora kinase A gene (AURKA) and N-Myc proto-oncogene (MYCN), as well as expression of luminal epithelial markers and proneural transcription factors [24]. This evidence concerns the gene TP53 and posterior cortical atrophy.